- Type of Event: Earnings Conference Call to discuss Audited Standalone and Consolidated Financial Results.
- Date and Time: The call was held on Wednesday, May 20, 2026, at 03:00 P.M. (IST).
- Purpose: To discuss the company's financial performance for Q4 and FY26 and provide a strategic update.
- Management Participants: The call was joined by Mr. Mayank Singhal (Vice Chairperson and Managing Director), Mr. Sanjay Agarwal (Group Chief Financial Officer), Dr. Atul Gupta (CEO, CSM Agchem), Mr. Jagresh Rana (Global CEO, PI AgSciences), and Dr. Ramesh Subramanian (Global CEO, PI Health Sciences).
- Availability of Materials: The transcript of the call is made available on the Company's website at https://www.piindustries.com/investor/disclosure/stock-exchange-filings/earning-call-transcript-and-audio-recordings/.
- Financial Period Discussed: The call discussed results for the quarter and financial year ended March 31, 2026 (Q4 FY26).
- Forward-Looking Statements: The management discussed expectations for FY27, including a positive growth outlook led by recovery in exports in the second half, new product launches (including the first homegrown NCE in the domestic business), and the scaling up of the pharma and biologicals segments. They expect the Effective Tax Rate (ETR) to inch up to 24% in FY27 and beyond.
- Compliance: The document is a regulatory filing submitted pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (LODR) Regulations, 2015. The transcript includes a standard disclaimer noting it may contain errors.
Financial Highlights & Strategic Updates
FY26 Performance:
- Consolidated Revenue: ₹ 67,137 million
- EBITDA Margin: 25%
- Net Cash Position: ₹ 34,265 million
- Gross Margin: 58% for the quarter and the year
- Effective Tax Rate (ETR): 22% for FY26
- Trade Working Capital: 139 days of sales
Business Segment Performance:
- Agrochemicals: The global market continued a multi-year downcycle. Exports declined due to lower volumes. The company commercialized 5 new molecules in AgChem Exports and launched 4 new products in Domestic Agri Brands. New products now contribute 18% of AgChem Exports.
- Pharma (PI Health Sciences): Delivered 40% revenue growth for the full year. The business is focused on building a differentiated CRDMO (Contract Research, Development, and Manufacturing Organization) model.
- Biologicals: This segment has been compounding at over 20%+. The company highlighted the launch of a novel foliar-applied biological nematode product in the US, following launches in Brazil and Mexico.
- New Chemical Entity (NCE): The company's first in-house NCE, Pioxaniliprole, is preparing for launch in the Indian market. Plans for global regulatory filings and strategic partnerships are underway, with applications outside India expected by the end of CY26 or next year.
- Electronic Chemicals: The company is working on 4-5 molecules in this niche area, targeting revenues of $80-100 million in the next 4-5 years.
Capex & Investments:
- Capex for FY26 was approximately ₹1,100 crore, spread across agrochemicals, pharma, and R&D. Key projects included a Kilo facility in the Lodi plant and a Flow MPP.
- Capex guidance for FY27 is ₹700-800 crore.
- Capacity utilization for FY26 was around 80%.
- Contract assets reduced from ~₹1,000 crore in Dec '25 to ₹700 crore in Mar '26 and are expected to hover around this level.
Management Change:
- Mr. Rajnish Sarna, Joint Managing Director, has stepped down from executive responsibilities to focus on his health. He will continue as a Non-Executive Director on the Board. Mr. Sanjay Agarwal (Group CFO) will now lead investor engagement.
Additional Notes Section
- The document is the enclosing letter for the submitted transcript; the transcript itself is the primary attachment.
- The summary includes financial data and forward-looking statements that were explicitly disclosed during the earnings call.
- Logistical details like dial-in numbers were part of the original call invite but are not included in this transcript summary.